Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322725 · ClinicalTrials.gov registry record
Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review
A clinical trial, sponsored by University of New Mexico.
- Terminated
- Registry status
- 25
- Enrollment target
NCT00322725 is a clinical trial that was terminated before completion, run by University of New Mexico. The registered enrollment target is 25 participants.
The verdict
NCT00322725 was terminated before completion, sponsored by University of New Mexico.
- TERMINATED
- Registry status
- 25 participants
- Enrollment target
Study Summary
1.11 Retrospectively evaluate for a correlation between tumor response and changes in systolic/diastolic/mean arterial blood pressures in patients treated with bevacizumab, with or without chemotherapy, with a wide variety of metastatic malignancies. 1.12 Retrospectively evaluate for differences in tumor response between patients with and without pre-existing hypertension treated with bevacizumab plus or minus chemotherapy with a wide variety of metastatic malignancies. 1.21 Determine if there were differences in bevacizumab induced hypertension rates between different tumor types. 1.22 Evaluate for differences in bevacizumab induced hypertension rates between males and females. 1.23 Examine if there were associations between a particular chemotherapeutic agent(s), that may have had an increased propensity of inducing hypertension when combined with bevacizumab.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322725
The ClinicalTrials.gov registry entry for NCT00322725 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00322725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00322725 about?
NCT00322725 is a clinical study titled "Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review". 1.11 Retrospectively evaluate for a correlation between tumor response and changes in systolic/diastolic/mean arterial blood pressures in patients treated with bevacizumab, with or without chemotherapy, with a wide variety of metastatic malignancies. 1.12 Retrospectively evaluate for differences in...
What is the current status of trial NCT00322725?
This trial is currently terminated. The enrollment target is 25 participants. The study started on 2006-02. Estimated completion is 2009-04.
Who is sponsoring clinical trial NCT00322725?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.